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Here we report the development of a straightforward 
synthetic procedure for the preparation of spirocyclic 
endoperoxides as synthetic analogues of the natural product 
dihydroplakortin. Peroxides here presented are more 
potent antiplasmodials than dihydroplakortin itself and we 
proved for the first time their antimalarial activity in vivo.  
Cyclic	   peroxides	   such	   as	   1,2-­‐dioxolanes,	   1,2,4-­‐trioxanes	   and	   1,2-­‐dioxanes	   are	   a	   class	   of	   organic	   compounds	   with	   interesting	  pharmacological	   properties	   and	   widely	   represented	   in	   nature.	  Artemisinin	   (ART)	   is	   an	   endoperoxide-­‐based	   natural	   product,	  which	   is	   highly	   effective	   against	   clinically	   relevant	   P.	   falciparum	  strains	   responsible	   for	   human	   malaria.	   Currently,	   the	   so-­‐called	  artemisinin-­‐based	   combination	   therapies	   (ACT)	   are	   employed	   as	  first	  line	  treatment	  in	  most	  malaria	  endemic	  countries,	  adhering	  to	  WHO	   recommendations.1-­‐3	   However,	   lower	   susceptibility	   to	  artemisinins	   is	   being	   reported	   from	   highly	   malaria	   endemic	  regions.4	   So,	   novel	   peroxides	   characterized	   by	   different	   structural	  features	   could	   delay	   the	   potential	   selection	   of	   P.	   falciparum	  resistant	  strains.5	  Moreover,	  cost	  associated	  to	  the	  extraction	  of	  this	  drug	   or	   to	   synthetic	   precursors	   from	   natural	   sources,	   prompted	  researcher	   at	   developing	   synthetic	   peroxides	   as	   low-­‐cost	  alternatives	  to	  ART.6	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Since	   several	   years	   we	   are	   engaged	   in	   the	   design	   of	   suitable	  synthetic	   strategies	   for	   the	   preparation	   of	   antimalarial	  endoperoxides.7-­‐10	   In	   particular	   we	   performed	   the	   first	  stereoselective	   synthesis	  of	  9,10-­‐dihydroplakortin	   (DHP,	  1,	   Figure	  1),10	   a	   natural	   product	   endowed	   with	   interesting	   antiplasmodial	  properties.11	   We	   also	   reported	   the	   development	   of	   novel	  endoperoxides	   as	   synthetic	   analogues	   of	   DHP	   characterized	   by	   a	  bicyclic	   tetrahydrofuro[2,3-­‐c][1,2]dioxane	   core.	   The	   synthetic	  peroxide	  2	  (Figure	  1)	  was	  the	  most	  potent	  compound	  of	  the	  series	  and	   showed	   higher	   antimplasmodial	   potency	   than	  dihydroplakortin.	  The	  major	  limitation	  of	  these	  analogues	  was	  their	  synthesis	   as	   an	   inseparable	   mixture	   of	   diastereoisomers.7	   The	  structure-­‐activity	  relationships	  (SARs)	  for	  this	  class	  of	  compounds	  were	  rationalized	  on	  the	  basis	  of	  the	  mechanism	  of	  action	  proposed	  for	  ART.	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Scheme	   1	   General	   synthesis	   of	   endoperoxides	   3-­‐9.	   [Reaction	   conditions:	   a)	  
Co(thd)2,	  Et3SiH,	  O2,	  t-­‐BuOOH	  (5	  M	  in	  nonane),	  1,2-­‐dichloroethane	  (1,2-­‐DCE),	  25	  
°C,	  4	  h;	  b)	  DIBAL,	  DCM,	  -­‐78	  °C,	  1.5	  h;	  d)	  TMSOTf,	  DCM,	  -­‐78	  °C,	  5	  min.]	  
Although	  the	  mechanism	  of	  action	  of	  ART	  is	  still	  debated,12	  it	  seems	  that	   the	  peroxide	  bond	   is	  activated	  within	   the	   food	  vacuole	  of	   the	  parasite,	   a	   specialized	   organelle	   accommodating	   the	   hydrolysis	   of	  hemoglobin,	   a	   necessary	   source	   of	   amino	   acids	   for	   the	   parasites.	  During	   this	   process,	   free	   Fe(II)-­‐heme	   is	   released	   and	   reacts	   with	  the	   peroxide	   bond	   of	   ART	   to	   form	   an	   O-­‐centered	   radical,	   that	  probably	  undergoes	  a	  1,5-­‐H	  shift	  to	  form	  a	  highly	  toxic	  C-­‐centered	  radical,13,14	   ultimately	   responsible	   of	   the	   antiplasmodial	   activity.	  The	   formation	   of	   C-­‐centered	   radicals	   has	   also	   been	   proposed	   for	  several	   synthetic	   endoperoxides,	   comprising	   DHP.15-­‐17	   For	   our	  synthetic	   peroxides,	   we	   found	   that	   subtle	   modifications	   of	   the	  substituent	   at	   C3,	   affecting	   the	   distance	   between	   the	   C5	   of	   the	  lateral	  chain	  and	  the	  O2	  of	  the	  peroxide	  bridge	  (C5-­‐O2	  distance	  <	  3	  Å	  for	   optimal	   activity),	   had	   strong	   impact	   on	   the	   antiplasmodial	  potency,	   in	   line	   with	   the	   mode	   of	   action	   of	   ART	   and	   DHP.7	   As	   a	  continuation	   of	   our	   previous	   work,	   we	   were	   interested	   in	  developing	   suitable	   synthetic	   strategies	   aimed	   at	   modifying	   the	  lateral	  chain	  at	  C3	  of	  the	  bicyclic	  skeleton	  (3-­8)	  and	  the	  size	  of	  the	  rings	   forming	   the	   bicyclic	   system	   (9-­11)	   reducing	   the	   number	   of	  chiral	  centers.	  In	  particular,	  we	  were	  interested	  in	  the	  synthesis	  of	  spiro-­‐derivatives	   6-­8	   that	   lack	   the	   stereogenic	   center	   at	   C3	   and	  represent	  a	  further	  simplification	  of	  this	  class	  of	  compounds.	  As	   described	   in	   Scheme	   1,	   a	   three-­‐step	   reaction	   protocol	   was	  employed	  for	  the	  assembly	  of	  the	  bicyclic	  core	  starting	  from	  olefin	  intermediates	   12a-­d	   and	   13a-­c.	   The	   first	   step	   of	   the	   protocol	  consisted	   in	   the	   Mukaiyama	   peroxysilylation	   reaction18,19	   of	   the	  double	  bond	  of	  intermediates	  12a-­d	  and	  13a-­c	  to	  afford	  peroxides	  
14a-­d	  and	   15a-­c,	   respectively.	   The	  Mukaiyama	   reaction	  proceeds	  regioselectively	  at	  the	  more	  substituted	  carbon	  of	  the	  double	  bond.	  Subsequently	   the	   lactone	   functionality	   was	   reduced	   to	   the	  corresponding	   lactol	   by	   using	   diisobutylaluminum	   hydride	  (DIBAL).	   Finally,	   trimethylsilyl	   triflate	   (TMSOTf)-­‐promoted	  simultaneous	   deprotection	   and	   cyclization	   of	   the	   resulting	   lactols	  afforded	  the	  cyclised	  endoperoxides	  3-­5,	  isolated	  as	  inseparable	  	  
 
Scheme	   2	   Synthesis	   of	   intermediates	   12a,d	   and	   13c.	   [Reaction	   conditions:	   a)	  
triethyl	   2-­‐phosphonopropionate	   (for	   17a),	   or	   triethyl	   phosphonoacetate	   (for	  
17b),	  NaH,	  THF,	  0	  °C,	  1	  h,	  then	  25	  °C,	  2	  h;	  b)	  DIBAL,	  DCM,	  -­‐78	  °C,	  1.5	  h;	  c)	  I2,	  PPh3,	  
imidazole,	  1:3	  MeCN/Et2O,	  0	  °C,	  30	  min	  (from	  17a,c)	  or	  KI,	  BF3•Et2O,	  dioxane,	  25	  
°C,	  3	  h	  (from	  17b);	  d)	  i.	  19,	  LiHMDS,	  THF,	  -­‐78	  °C,	  30	  min;	  ii.	  17a-­‐c,	  -­‐78	  °C,	  30	  min,	  
then	  25	  °C,	  2	  h.]	  
 
Scheme	  3	  Synthesis	  of	  intermediates	  12b,c.	  [Reaction	  conditions:	  a)	  CeCl3x7H2O,	  
10-­‐13%	  NaOCl,	   1:1	  DCM/H2O,	  25	   °C,	  14	  h;	  b)	  NaI,	   acetone,	  25	   °C,	  18	  h;	   c)	  CuI,	  
THF,	  25	  °C	  24	  h,	  80	  °C,	  5	  h;	  d)	  MsCl,	  Et3N,	  Et2O,	  0	  °C,	  12	  h;	  (e)	  LiI,	  Et2O,	  sonication,	  
25	  °C,	  3	  h;	  (f)	  i.	  19,	  LiHMDS,	  THF,	  -­‐78	  °C,	  30	  min;	  ii.	  22a,c,	  -­‐78	  °C,	  30	  min,	  then	  25	  
°C,	  2	  h.]	  
 
Scheme	  4	  Synthesis	  of	  intermediates	  13a,b.	  [Reaction	  conditions:	  a)	  19,	  LDA,	  -­‐78	  
°C,	  20	  min,	  then	  25	  °C,	  8	  h;	  (b)	  SOCl2,	  pyridine,	  25	  °C,	  2	  h.]	  
 
Scheme	  5	   Synthesis	  of	   rac-­‐11.	   [Reaction	   conditions:	   a)	  NaBH4,	   EtOH,	  0	   °C,	   1	  h,	  
then	  25	  °C,	  12	  h;	  b)	  Co(thd)2,	  Et3SiH,	  O2,	  t-­‐BuOOH	  (5	  M	  in	  nonane),	  1,2-­‐DCE,	  25	  
°C,	  4	  h;	  c)	  MsCl,	  Et3N,	  DCM,	  0	  °C,	  2	  h.	  
mixtures	  of	  diastereoisomers,	   and	   spiroperoxides	  6-­9	   obtained	  as	  racemates.	  Following	  a	  slightly	  modified	  protocol,	   the	  synthesis	  of	  endoperoxide	   10	   is	   reported	   as	   Supplementary	   Information	   (SI).	  The	   synthesis	   of	   intermediates	   12a,d	   and	   13c	   is	   described	   in	  Scheme	  2.	  1-­‐Adamantylaldehyde	  16a	  and	  cyclohexanone	  16b	  were	  submitted	  to	  the	  Horner–Wadsworth–Emmons	  olefination	  reaction	  to	   afford	   the	   α,β-­‐unsaturated	   esters	   17a,b.	   DIBAL-­‐mediated	  reduction	  of	  above	  esters	  17a,b	  and	  of	  commercially	  available	  ester	  










12a, R1 = Me, R2 = 1-Ada
12b, R1 = CyHex, R2 = H
12c, R1 = CyPent, R2 = H

















13a, R1,R2 = -(CH2)5-, n = 0
13b, R1,R2 = Ada, n = 0
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16a, R1 = H, R2 = Ada




R2 17a, R1 = H, R2 = Ada, R3 = Me
17b, R1,R2 = -(CH2)5-, R3 = H














20a, R1 = Cyclohexyl











22a, R = CyHex
22b, R = 1-Ada















26a, R1 = cyclopentyl
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subsequently	  converted	  into	  the	  iodides	  18a-­c.	  While	  iodides	  18a,c	  were	   obtained	   by	   treatment	   of	   the	   alcohols	   with	   iodine,	  triphenylphosphine,	   and	   imidazole,	   iodide	   18b	   could	   not	   be	  obtained	  by	  using	  the	  same	  protocol.	  18b	  was	  instead	  obtained	  by	  treatment	   of	   the	   alcohol	   precursor	   with	   potassium	   iodide	   in	   the	  presence	   of	   boron	   trifluoride.	   Iodides	   18a-­c	   were	   next	   used	   to	  alkylate	  lactone	  19	  using	  lithium	  hexamethyldisilylamide	  (LiHMDS)	  as	   the	  base	   to	  afford	  12a,d	  and	  13c.	   Intermediates	  12b,c,	  bearing	  cyclohexyl	  and	  cyclopentyl	  substituents,	  were	  prepared	  as	  reported	  in	   Scheme	  3.	  The	   synthesis	   of	   an	   analogue	  bearing	   an	   adamantyl-­‐	  radical	   at	   the	   same	   position	  was	   also	   attempted	  without	   success.	  Accordingly,	   cyclohexyl	   and	   1-­‐adamantyl	   derivatives	   20a,b	   were	  treated	   with	   cerium	   chloride	   as	   a	   Lewis	   acid	   and	   sodium	  hypochlorite	   as	   the	   oxidizing	   agent	   to	   afford	   chloromethyl	  derivatives	  21a,b	   in	   reasonable	   yields.	   Intermediates	  21a,b	   were	  in	   turn	   converted	   into	   the	   corresponding	   iodides	   22a,b.	  Intermediate	   22c	   was	   synthesized	   starting	   from	   25,	   in	   turn	  
prepared	   following	   a	   different	   synthetic	   approach	  by	   reacting	   the	  Grignard	   reagent	  23,	   formed	   in	   situ,	  with	   propargyl	   alcohol	  24.20	  The	  resulting	  primary	  alcohol	  25	  was	  then	  converted	  to	  22c	  via	  a	  mesyl	   ester	   intermediate	   that	   was	   sonicated	   in	   the	   presence	   of	  lithium	  iodide	  to	  afford	  the	  desired	  iodide	  22c	  in	  good	  overall	  yield.	  Iodides	   22a-­c	   were	   used	   as	   alkylating	   agents	   for	   the	   enolate	   of	  lactone	   19.	   While	   22a,c	   smoothly	   furnished	   the	   corresponding	  alkylation	   products,	   the	   same	   reaction	   performed	   with	   the	  adamantyl	   derivative	  22b	   failed,	   probably	  due	   to	   its	   higher	   steric	  hindrance.	   For	   the	   synthesis	   of	   intermediates	   13a,b	   (Scheme	   4),	  alcohol	   intermediates	   27a,b,	   in	   turn	   obtained	   by	   aldol	  condensation	  of	   aldehydes	  26a,b	  with	  19	   in	   the	  presence	   lithium	  diisolpropylamide	   (LDA),	   were	   dehydrated	   to	   the	   corresponding	  olefins.	   Finally,	   dioxolane	   rac-­‐11	   was	   synthesized	   as	   described	   in	  Scheme	  5.	  The	  carbonyl	  group	  of	  the	  commercially	  available	  ketone	  
28	  was	  reduced	  using	  sodium	  borohydride	  and	  the	  double	  bond	  	  
	  
Table 1 Antiplasmodial activity, calculated O1,O2---Fe(II)-heme distancesb, and ΔGbind (kcal/mol)c  





























5.3 1.1 3.89 3.03 -23.82 
7 
 
0.84 0.47 2.81 2.24 -28.43 
8 
 
0.61 0.16 2.18 2.16 -30.69 
9 
 
>20 >17.0 3.36 3.90 -19.76 
10 
 
8.5 >25 2.40 2.99 -24.46 
11 
 
7.2 3.2 2.34 3.22 -22.64 
17  0.86 0.44 2.20 2.27 -31.04 
ART  0.029 0.012 2.14 2.10 -43.13 
CQ  0.015 0.228 - - - 
aIC50 values are the mean of at least three determinations in duplicate. Standard errors were all within 10% of the mean. bThe distances were calculated and 
reported in Å by means of measurement tool implemented in Maestro graphical interface from the poses obtained by docking calculation; cThe binding energy 
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was	   hydroperoxysilylated	   to	   29	   employing	   Mukaiyama	   reaction	  conditions.	   Treatment	   of	  29	  with	  methanesulfonyl	   chloride	   in	   the	  presence	  of	  triethylamine	  directly	  afforded	  the	  cyclization	  product	  
rac-­‐11.	  The	   antiplasmodial	   activity	   of	   the	   novel	   endoperoxides	  3-­11	   was	  tested	   against	   two	   laboratory	   P.	   falciparum	   strains,	   the	  chloroquine-­‐sensitive	   (CQ-­‐S)	   D10	   and	   the	   chloroquine-­‐resistant	  (CQ-­‐R)	  W2,	  accordingly	  to	  described	  procedures.7	  The	  resulting	  IC50	  are	  reported	  in	  Table	  1.	  	  To	  understand	  the	  modulation	  of	  antiplasmodial	  potency	  observed	  for	   the	   synthesized	   compounds,	   we	   in	   depth	   analyzed	   the	  interaction	  of	  the	  peroxide	  moiety	  of	  compounds	  4-­11	  with	  Fe(II)-­‐heme	  (which	   is	   the	   first	  and	   the	  key	  step	   for	   the	   formation	  of	   the	  toxic	   radical	   species)	   by	   molecular	   docking	   analysis	   employing	  Glide	  software,	  after	  structure	  optimization	  performed	  by	  using	  ab	  
initio	  calculation	  employing	  the	  Jaguar	  software.22,23	  Endoperoxides	  here	   reported	   have	   been	   produced	   and	   tested	   as	   mixtures	   of	  diastereoisomers	   (3-­5)	   or	   as	   racemates	   (6-­11),	   while	   docking	  studies	  were	  performed	  for	  each	  enantiomer.	  As	  expected,	  heme	  is	  unable	   to	   discriminate	   between	   enantiomers24	   and	   no	   differences	  in	   the	   binding	  mode	   of	   each	   enantiomeric	   couple	  were	   observed.	  Based	   on	   our	   molecular	   docking	   calculations,	   we	   found	   a	   good	  correlation	  between	  the	  distance	  of	  oxygen	  atoms	  from	  the	  reactive	  heme	  iron	  center	  and	  the	  antimalarial	  activity	  (Table	  1).	  In	  fact,	  the	  compounds	   that	   display	   a	   larger	   distance	   of	   the	   peroxide	  moiety	  from	   the	   iron	   center	   such	   as	   compound	  6,	  9-­‐11	   were	   found	   less	  potent	   in	   vitro	   than	   compounds	   3-­5,7,8	   exhibiting	   a	   shorter	  distance.	   For	   example,	   peroxide	   4	   (one	   of	   the	   most	   active	  compound	  in	  the	  set)	  displaying	  a	  very	  short	  distance	  between	  the	  peroxide	   oxygen	   atoms	   and	   the	   iron	   center	   (Table	   1)	   and	   both	  atoms	  could	  be	  able	  to	  coordinate	  the	  heme	  iron.	  On	  the	  contrary,	  the	   inactive	  analogue	  9	  does	  not	  possess	   the	  appropriate	  distance	  to	  interact	  with	  heme	  iron.	  	  For	  comparison,	  distances	  calculated	  for	  the	  reference	  compounds	  ART	  and	  DHP	  are	  also	  in	  good	  agreement	  with	  a	  correct	  interaction	  with	  heme	  (Table	  1	  and	  Figure	  S1	   in	  the	  Supporting	  Information).	  Also	  the	  free-­‐binding	  energy21	  (ΔGbind)	  calculated	  for	  all	  complexes	  (Table	   1),	   displayed	   a	   good	   correlation	   with	   antiplasmodial	  potency,	   being	   around	   -­‐20	   kcal/mol	   for	   inactive	   compounds	   (9),	  comprised	   between	   -­‐20	   and	   -­‐25	   kcal/mol	   for	   compounds	   in	   the	  micromolar	  range	  (6,10,11),	  and	  <	  -­‐25	  kcal/mol	  for	  compounds	  in	  the	  low	  micromolar	  range	  (1,	  3-­5,7,8).	  It	  is	  worth	  noticing	  that	  ART	  presents	   a	   calculated	   ΔGbind	   well	   below	   the	   value	   found	   for	   the	  spiroperoxides	   here	   presented,	   consistent	   with	   its	   nanomolar	  antiplasmodial	   potency.	   Compound	   8,	   displaying	   an	   estimated	  ΔGbind	   of	   -­‐30.69	   kcal/mol,	   is	   the	   most	   potent	   plakortin-­‐related	  endoperoxide	   described	   to	   date.11	   Accordingly,	   both	   epimers	   of	  compounds	  4	  and	  5	   (Figure	  2A-­‐D)	   interact	  with	  heme	  in	  a	  similar	  fashion.	  However,	  the	  larger	  steric	  hindrance	  of	  the	  cyclohexyl	  ring	  of	  4	  with	  respect	   to	   the	  cyclopentyl	  ring	  of	  5	  results	   in	  a	  stronger	  hydrophobic	   interaction	   with	   heme	   for	   4.	   For	   the	   couple	   of	  analogues	   6	   and	   7	   (Figure	   3A,B),	   the	   steric	   hindrance	   of	   the	  cyclohexyl	   ring	   physically	   hampers	   the	   accommodation	   of	  6	   for	   a	  strong	   interaction	   with	   Fe(II)-­‐heme	   (Figure	   2A),	   while	   the	  cyclopentyl	   ring	   of	   7	   (Figure	   3B)	   has	   a	   reduced	   steric	   hindrance	  and	  is	  well	  tolerated	  allowing	  both	  O2	  and	  O1	  of	  the	  peroxide	  	  
 
Figure	  2	  Docked	  poses	  of	  both	  epimers	  of	  4	  (panels	  A	  and	  B	  in	  gray	  sticks)	  and	  5	  
(panels	  C	  and	  D)	  in	  complex	  with	  heme	  (green	  balls	  and	  sticks),	  charged	  iron	  was	  
colored	   cyan	   and	   represented	   by	   CPK	   model.	   The	   potential	   ligand-­‐metal	  
coordination	   bonds	   are	   reported	   as	   black-­‐green	   dotted	   lines.	   The	   picture	   was	  
generated	  by	  Maestro.25	  
 
Figure	  3	  Docked	  poses	  of	  6-­‐9	  (gray	  sticks;	  A,	  B,	  C,	  and	  D,	  respectively)	  in	  complex	  
with	   heme	   (green	   balls	   and	   sticks),	   charged	   iron	   was	   colored	   cyan	   and	  
represented	   by	   CPK	  model.	   The	   potential	   ligand-­‐metal	   coordination	   bonds	   are	  
reported	  as	  black-­‐green	  dotted	  lines.	  The	  picture	  was	  generated	  by	  Maestro.25	  
system	  to	   interact	  with	  Fe(II)-­‐heme.	  Docking	  studies	  (Figures	  2,3)	  highlighted	  that	  subtle	  differences	  in	  the	  structure	  of	  the	  peroxide	  and	   in	   particular	   of	   the	   size	   and	   shape	   of	   their	   side	   chains	   are	  responsible	   for	  a	   fine-­‐tuning	  of	   the	  antiplasmodial	  activity.	  On	  the	  other	   hand,	   the	   bulky	   adamantane	   ring	   (8,	   Figure	   3C)	   is	   able	   to	  maximize	   hydrophobic	   interactions	   with	   the	   planar	  protoporphyrin-­‐IX	   ring	   at	   the	   same	   time	   maintaining	   a	   correct	  orientation	  of	  both	  the	  peroxide	  oxygens	  for	  their	  interaction	  with	  Fe(II)-­‐heme,	   thus	  resulting	   in	  an	  overall	   improved	  ΔGbind	  and,	  as	  a	  consequence,	   higher	   antiplasmodial	   potency.	   Finally,	   the	   seven-­‐membered	  ring	  of	  compound	  9	  (Figure	  3D)	  is	  not	  tolerated	  since	  it	  hampers	  a	  favourable	  conformation	  for	  reaching	  the	  right	  distance	  to	   iron	   atom	   contained	   in	   the	   protoporphyrin	   ring	   (Figure	   3D).	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Spiroperoxide	  8,	  the	  most	  potent	  antiplasmodial	  agent	  of	  the	  series,	  was	  submitted	  to	  a	  preliminary	  in	  vivo	  evaluation	  in	  the	  P.	  berghei	  mouse	   model	   of	   malaria	   using	   the	   Peters	   4-­‐day	   test.26	   After	  administration	  of	  8	  at	  a	  daily	  dose	  of	  100	  mg/kg	  (i.p.),	  mice	  showed	  a	   72.5%	   reduction	   in	   parasitaemia.	   Notably,	   compound	  8	   did	   not	  elicit,	   at	   the	   concentration	   used	   in	   the	   in	   vivo	   study,	   any	   sign	   of	  toxicity	   in	   mice	   consistently	   with	   its	   determined	   in	   vitro	   toxicity	  against	  mouse	  fibroblasts	  NIH3T3	  (TC50	  =	  150	  µM).	  In	   conclusion,	   we	   herein	   presented	   the	   development	   of	   a	  straightforward	   synthetic	   procedure	   for	   the	   preparation	   of	  spiroperoxides	   as	   racemic	  mixtures	   endowed	  with	   antiplasmodial	  activity	  against	  P.	  falciparum	  CQ-­‐S	  and	  CQ-­‐R	  strains.	  Being	  heme	  an	  achiral	   target,	   compounds	   were	   tested	   as	   racemates	   since	   no	  difference	  on	  antiplasmodial	  activity	  for	  each	  enantiomer	  could	  be	  expected.24	  Molecular	  modelling	  studies	  highlighted	  key	  molecular	  features	  responsible	  for	  activity	  and	  potency,	  and	  will	  be	  useful	  for	  further	  optimizing	  their	  in	  vitro	  potency.	  Moreover,	  we	  have	  herein	  for	   the	   first	   time	   provided	   evidence	   that	   plakortin-­‐derived	  synthetic	   analogues	   do	   have	   antimalarial	   activity	   in	   vivo. The straightforward	   synthetic	   approach	   to	   spirocyclic	   endoperoxides	  may	  pave	  the	  way	  to	  the	  development	  of	  more	  potent	  analogues	  in	  vivo.	  The	   Authors	   thank	   MIUR	   for	   financial	   support.	   S.	   B.	   thanks	   S-­‐IN	  Soluzioni	  Informatiche	  for	  technical	  support.	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